The EFTISARC-NEO trial, with a data cut-off of 20 October 2024, also showed 71.4% of patients achieved a pathologic response ...

More sarcoma patients are beating the odds with pembrolizumab! This immunotherapy can change the treatment for limb sarcomas ...

Adding a PD-1 inhibitor to standard of care improved disease-free survival (DFS) in stage III soft-tissue sarcoma of the ...

Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the ...

NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based ...

Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft ...

The clinical trials are sponsored by IO Biotech and conducted in collaboration with Merck, which is supplying pembrolizumab. IO Biotech maintains global commercial rights to IO102-IO103. KEYTRUDA® is ...

“We have already adopted the strategy of a checkpoint inhibitor [pembrolizumab] after chemoradiation for stage ... tertiary ...

Amidst this rapidly evolving landscape, white label AI tools have become pivotal for companies seeking to harness the power of AI without the extensive resources typically required for developing such ...

The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd)- ...

Today's label printers range from small desktop units for file-folder paper labels to industrial-grade ones for labeling cables with plastic strips. Here's how to pick the right labeler ...

As the Lower House election approaches this Sunday, a barrage of articles profuse with political labels is appearing in the media. But none of the articles explain what the labels mean ...